Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carrageenans inhibit growth-factor binding

R Hoffman1

  • 1Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Cambridge, U.K.

The Biochemical Journal
|January 15, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental Toxins Found Historically in the Polycythemia Vera Cluster Area and their Potential for Inducing DNA Damage.

Journal of environmental & analytical toxicology·2021
Same author

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).

Leukemia research·2019
Same author

Which positive factors give general practitioners job satisfaction and make general practice a rewarding career? A European multicentric qualitative research by the European general practice research network.

BMC family practice·2019
Same author

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Leukemia·2019
Same author

Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia?

Leukemia research·2018
Same author

Pan-Caspase Inhibitor Prevents Anti-CD3 Mediated T-Lymphocyte Proliferation.

TheScientificWorldJournal·2018
Same journal

Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.

The Biochemical journal·2026
Same journal

Persistence without turnover: the RhoG G12E mutant highlights the role of nucleotide cycling in RhoG signaling.

The Biochemical journal·2026
Same journal

Alternative Splicing of Rice Chloroplastic CuZn Superoxide Dismutase, OsCSD2: Impact on expression and protein characteristics.

The Biochemical journal·2026
Same journal

Difference and similarity between the ubiquitous secretory pathway Ca2+-ATPases, SERCA2b, and SPCA1a.

The Biochemical journal·2026
Same journal

A molecular perspective on dimethylarginine dimethylaminohydrolases structure and function.

The Biochemical journal·2026
Same journal

Proteolytic coordination of the OXPHOS Life Cycle.

The Biochemical journal·2026
See all related articles

Carrageenans, sulfated carbohydrates, selectively block growth factors like bFGF, TGF-β1, and PDGF. This discovery highlights their potential therapeutic use in treating growth factor-related disorders.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Carrageenans are sulfated polysaccharides with diverse biological activities.
  • Growth factors play critical roles in cellular processes, and their dysregulation is implicated in various diseases.

Purpose of the Study:

  • To investigate the inhibitory effects of different carrageenan types on the binding of key growth factors.
  • To determine the selectivity and potency of carrageenans as growth factor antagonists.

Main Methods:

  • In vitro assays were used to measure the inhibition of growth factor binding by various carrageenan fractions.
  • Dose-response curves were generated to determine IC50 values for each carrageenan-growth factor interaction.

Main Results:

Related Experiment Videos

  • Carrageenans demonstrated selective inhibition of basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF-β1), and platelet-derived growth factor (PDGF) binding.
  • Iota-carrageenan was the most potent bFGF antagonist, kappa-carrageenan inhibited PDGF, and lambda-carrageenan was most effective against TGF-β1.
  • No significant inhibition was observed for insulin-like growth factor 1 or transforming growth factor alpha binding.

Conclusions:

  • Carrageenans act as selective antagonists for specific growth factors.
  • These findings suggest potential therapeutic applications for carrageenans in managing conditions characterized by excessive growth factor activity.